Enliven Therapeutics (ELVN) Current Assets (2019 - 2026)

Enliven Therapeutics has disclosed Current Assets across 8 years of filings, most recently posting $463.1 million for Q1 2026.

• Current Assets for Q1 2026 came in at $463.1 million, up 57.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $463.1 million (up 57.36% YoY), and the FY2025 annual result was $474.9 million, up 49.27% from the prior year.
• Current Assets came in at $463.1 million for Q1 2026 at Enliven Therapeutics, down from $474.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $495.6 million in Q2 2025 to a low of $59.1 million in Q3 2022.
• The 5-year median for Current Assets is $297.0 million (2024), against an average of $286.9 million.
• Across the five-year window, Current Assets sank 44.24% in 2022 and soared 354.46% in 2023, its largest moves.
• Enliven Therapeutics' Current Assets stood at $77.8 million in 2022, then soared by 242.3% to $266.2 million in 2023, then advanced by 19.53% to $318.1 million in 2024, then surged by 49.27% to $474.9 million in 2025, then slipped by 2.47% to $463.1 million in 2026.
• The last three Current Assets figures came in at $463.1 million (Q1 2026), $474.9 million (Q4 2025), and $482.7 million (Q3 2025), per Business Quant data.